Treatment with light benefits Alzheimer’s patients, Wayne State University finds

 

Detroit, Michigan (January 11, 2012) – Exposure to light appears to have therapeutic effects on Alzheimer’s disease patients, a Wayne State University researcher has found. In a study published recently in the Western Journal of Nursing Research, LuAnn Nowak Etcher, Ph.D., assistant professor of nursing, reported that patients treated with blue-green light were perceived by their caregivers as having improved global functioning.

 

Caregivers said patients receiving the treatment seemed more awake and alert, were more verbally competent and showed improved recognition, recollection and motor coordination. They also said patients seemed to recapture their personalities and were more engaged with their environment. Patients’ moods also were described as improved.

 

Etcher’s work is inspired by her interest in a phenomenon known as "sundowning," when Alzheimer’s patients sleep during the day, wake up later and may be up all night long. Part of her doctoral research was to utilize light, a common intervention for circadian disorders, to regulate the rest-activity patterns of women with Alzheimer’s.

 

This study, Etcher said, was an effort to address disagreement among researchers on the effect of therapeutic light in regulating rest-activity patterns in Alzheimer’s patients. The study involved 20 women older than age 65 with Alzheimer’s dementia from nursing homes in southeast Michigan. Each patient was assigned randomly to an experimental group receiving blue-green light treatments or a control group receiving dim red light.

 

A commercially available visor used to treat seasonal affective disorder and jet lag was used to administer the light to patients. Caregivers — patients’ family members and nursing facility personnel — were not told which type of light was hypothesized to have physiologic effects.

 

Although blue-green light recipients comprised the active experimental group, Etcher said she was surprised when some recipients of red light — the placebo group — also were reported as showing improvements, with caregivers saying their patients were calmer and had reduced resistance to care.

 

The level of effects varied, Etcher said, noting that while the blue-green group recipients were largely reported by caregivers as showing improvement, a few showed little to no effect from the treatments.

 

"Some of the rest-activity pattern disruptions that we see associated with Alzheimer’s dementia may not necessarily be circadian based," Etcher said. "They may be due to unmet needs, pain or other phenomena, and therefore would not respond to an intervention aimed at regulation of the circadian system."

 

Calling her study preliminary, she said it now needs to be replicated with a larger sample and different demographics.

 

In addition to ascertaining which behaviors are circadian based, establishing which methods are most appropriate to analyze data like Etcher’s requires exploration, she said. She is proposing further work that uses two different nonlinear analytic methods to examine sensitivity and specificity to detect change in circadian patterns, with a long-term goal of developing interventions to regulate those patterns to the benefit of patients’ overall function.

 

"If they sleep better at night, and are more awake during the day, they can eat, they can interact with other people and they can take advantage of other cueing agents in the environment," she said. "In addition to light during daytime and darkness during the nighttime, smells at mealtimes, food intake, interactions — all these things in conjunction help regulate our day."

 

 

Wayne State University is one of the nation’s pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.

 


 

Wayne State University, 11.01.2012 (tB)

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung